Structure Therapeutics, Inc. (GPCR)
21.94
+0.46
(+2.14%)
USD |
NASDAQ |
Oct 29, 16:00
22.18
+0.24
(+1.09%)
After-Hours: 05:04
Structure Therapeutics Enterprise Value : 226.06M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 226.06M |
| October 28, 2026 | 193.30M |
| October 27, 2026 | 198.28M |
| October 26, 2026 | 166.23M |
| October 23, 2026 | 172.64M |
| October 22, 2026 | 225.34M |
| October 21, 2026 | 231.04M |
| October 20, 2026 | 293.00M |
| October 19, 2026 | 231.04M |
| October 16, 2026 | 164.81M |
| October 15, 2026 | 243.86M |
| October 14, 2026 | 221.78M |
| October 13, 2026 | 252.41M |
| October 12, 2026 | 366.36M |
| October 09, 2026 | 482.44M |
| October 08, 2026 | 491.70M |
| October 07, 2026 | 563.63M |
| October 06, 2026 | 619.89M |
| October 05, 2026 | 628.44M |
| October 02, 2026 | 634.14M |
| October 01, 2026 | 727.43M |
| September 30, 2026 | 890.52M |
| September 29, 2026 | 991.65M |
| September 28, 2026 | 1.161B |
| September 25, 2026 | 1.222B |
| Date | Value |
|---|---|
| September 24, 2026 | 1.229B |
| September 23, 2026 | 1.224B |
| September 22, 2026 | 1.292B |
| September 21, 2026 | 1.285B |
| September 18, 2026 | 1.156B |
| September 17, 2026 | 1.163B |
| September 16, 2026 | 1.192B |
| September 15, 2026 | 1.437B |
| September 14, 2026 | 1.401B |
| September 11, 2026 | 1.417B |
| September 10, 2026 | 1.480B |
| September 09, 2026 | 1.600B |
| September 08, 2026 | 1.539B |
| September 04, 2026 | 2.035B |
| September 03, 2026 | 2.035B |
| September 02, 2026 | 2.068B |
| September 01, 2026 | 2.020B |
| August 31, 2026 | 1.933B |
| August 28, 2026 | 2.037B |
| August 27, 2026 | 2.169B |
| August 26, 2026 | 2.178B |
| August 25, 2026 | 2.219B |
| August 24, 2026 | 2.154B |
| August 21, 2026 | 2.160B |
| August 20, 2026 | 2.261B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.338T |
| Novo Nordisk A/S | 145.51B |
| Pfizer Inc. | 222.48B |
| Viking Therapeutics, Inc. | 2.720B |
| Liquidia Corp. | 3.907B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -106.33M |
| Total Expenses (Quarterly) | 106.33M |
| EPS Diluted (Quarterly) | -1.464 |
| Earnings Yield | -14.04% |
| Normalized Earnings Yield | -14.60 |